KR950016726A - 기능부전성 자궁 출혈을 억제하는 방법 - Google Patents

기능부전성 자궁 출혈을 억제하는 방법 Download PDF

Info

Publication number
KR950016726A
KR950016726A KR1019940034917A KR19940034917A KR950016726A KR 950016726 A KR950016726 A KR 950016726A KR 1019940034917 A KR1019940034917 A KR 1019940034917A KR 19940034917 A KR19940034917 A KR 19940034917A KR 950016726 A KR950016726 A KR 950016726A
Authority
KR
South Korea
Prior art keywords
compound
uterine bleeding
dysfunctional uterine
suppress
formula
Prior art date
Application number
KR1019940034917A
Other languages
English (en)
Inventor
피터 커헤인 패트릭
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950016726A publication Critical patent/KR950016726A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

본 발명은 효과량의 하기 일반식(I)의 화합물, 또는 그의 약학적으로 허용가능한 염 또는 용매화물을 기능부전성 자궁 출혈의 억제를 필요로 하는 인간에게 투여함을 포함하는, 상기 기능부전성 자궁출혈의 억제방법에 관한 것이다:
상기식에서,
R1및 R3는 독립적으로 수소, -CH3,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노, 헥사메틸렌이미노 및 피페리디노로 이루어진 그룹중에서 선택된다.

Description

기능부전성 자궁 출혈을 억제하는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 기능부전성 자궁 출혈의 억제에 사용하기 위한 하기 일반식(I)의 화합물, 또는 그의 약학적으로 허용가능한 염 또는 용매화물:
    상기식에서,
    R1및 R3는 독립적으로 수소, -CH3,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노 및 피페리디노로 이루어진 그룹중에서 선택된다.
  2. 제1항에 있언서, 상기 화합물이 그의 염산 염인 화합물.
  3. 제1항에 있어서, 예방적으로 투여되는 화합물.
  4. 제1항에 있어서, 상기 화합물이 하기 구조식의 화합물 또는 그의 염산 염인 화합물:
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940034917A 1993-12-21 1994-12-19 기능부전성 자궁 출혈을 억제하는 방법 KR950016726A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/171,391 1993-12-21
US08/171,391 US5446053A (en) 1993-12-21 1993-12-21 Methods of inhibiting dysfunctional uterine bleeding

Publications (1)

Publication Number Publication Date
KR950016726A true KR950016726A (ko) 1995-07-20

Family

ID=22623570

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940034917A KR950016726A (ko) 1993-12-21 1994-12-19 기능부전성 자궁 출혈을 억제하는 방법

Country Status (20)

Country Link
US (2) US5446053A (ko)
EP (1) EP0659417B1 (ko)
JP (1) JPH07215858A (ko)
KR (1) KR950016726A (ko)
CN (1) CN1109752A (ko)
AT (1) ATE168887T1 (ko)
AU (1) AU692490B2 (ko)
CA (1) CA2138510A1 (ko)
CZ (1) CZ321094A3 (ko)
DE (1) DE69412049T2 (ko)
DK (1) DK0659417T3 (ko)
ES (1) ES2119094T3 (ko)
GR (1) GR3027706T3 (ko)
HU (1) HUT71469A (ko)
IL (1) IL112037A (ko)
NO (1) NO944930L (ko)
NZ (1) NZ270167A (ko)
PH (1) PH31099A (ko)
RU (1) RU94044456A (ko)
ZA (1) ZA9410080B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102295878B1 (ko) 2021-06-16 2021-08-31 최경선 셀프용 등 지압기

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5847007A (en) 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
ATE377418T1 (de) 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
EP1133996A4 (en) * 1998-11-26 2003-04-02 Teikoku Hormone Mfg Co Ltd DRUG COMPOSITIONS WITH PERIODIC ADMINISTRATION
KR20020013533A (ko) 1999-05-04 2002-02-20 앤드류 맥린 안드로겐 글리코사이드와 그것의 안드로겐 활성
IN191020B (ko) 2000-03-28 2003-09-13 Dabur Res Foundation
DK1401446T3 (da) * 2001-05-22 2005-05-23 Lilly Co Eli Tetrahydroquinolinderivater til inhiberingen af sygdomme forbundet med estrogenmangel eller med en urelgelmæssig fysiologisk reaktion til endogent estrogen
WO2002094788A1 (en) * 2001-05-22 2002-11-28 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
TW200407124A (en) * 2002-06-25 2004-05-16 Wyeth Corp Use of thio-oxindole derivatives in treatment of hormone-related conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102295878B1 (ko) 2021-06-16 2021-08-31 최경선 셀프용 등 지압기

Also Published As

Publication number Publication date
NO944930D0 (no) 1994-12-19
AU692490B2 (en) 1998-06-11
JPH07215858A (ja) 1995-08-15
EP0659417B1 (en) 1998-07-29
GR3027706T3 (en) 1998-11-30
NZ270167A (en) 1997-08-22
CA2138510A1 (en) 1995-06-22
CN1109752A (zh) 1995-10-11
US5552416A (en) 1996-09-03
DK0659417T3 (da) 1998-12-07
ATE168887T1 (de) 1998-08-15
ZA9410080B (en) 1996-06-19
EP0659417A3 (en) 1995-09-06
ES2119094T3 (es) 1998-10-01
DE69412049T2 (de) 1999-01-14
NO944930L (no) 1995-06-22
IL112037A0 (en) 1995-03-15
RU94044456A (ru) 1996-10-10
DE69412049D1 (de) 1998-09-03
CZ321094A3 (en) 1995-08-16
HU9403663D0 (en) 1995-02-28
US5446053A (en) 1995-08-29
EP0659417A2 (en) 1995-06-28
IL112037A (en) 1999-03-12
HUT71469A (en) 1995-11-28
AU8156194A (en) 1995-06-29
PH31099A (en) 1998-02-05

Similar Documents

Publication Publication Date Title
KR950016744A (ko) 트롬빈을 저해하는 방법
KR950016732A (ko) 피부 및 질의 위축 억제방법
KR950016726A (ko) 기능부전성 자궁 출혈을 억제하는 방법
KR950016746A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR950016725A (ko) 폐 고혈압성 질병을 억제하는 방법
KR970706818A (ko) 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide)
KR950010893A (ko) 자궁내막증 억제 방법
KR950016738A (ko) 알쯔하이머 질병의 억제 방법
KR950016723A (ko) 자가면역 질병의 억제 방법
KR950010892A (ko) 자궁 섬유증 억제 방법
KR950016731A (ko) 지루 및 좌창의 억제 방법
KR950010890A (ko) 폐경기 증후군의 치료방법
KR950016737A (ko) 생리전 증후군/후기 황체 시기 불쾌성 질환 증상의 억제 방법
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
KR940005270A (ko) 뼈 손실 예방에 유용한 벤조티오펜
KR950016730A (ko) 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법
KR950010888A (ko) 평활근세포 증식 및 재발협착증을 억제하는 방법
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
KR950016740A (ko) 조직의 불완전한 회복을 저해하는 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR950010887A (ko) 연골 퇴화 억제 방법
KR950016735A (ko) 터너 증후군의 억제 방법
KR950016742A (ko) 폐경후 여성의 씨엔에스 질환을 억제하는 방법
KR950016734A (ko) 성적 조숙증의 억제방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid